

News Release

STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

Fisher & Paykel Healthcare announces results for the first half of the 2023 financial year

Auckland, New Zealand, 29 November 2022 - Fisher & Paykel Healthcare Corporation Limited (NZX:FPH, ASX:FPH) today announced its results for the first half of the 2023 financial year.

For the six months ended 30 September 2022, total operating revenue was \$690.6 million, above the \$670 million guided by the company in its August trading update.

While revenue was down 23% on the first half of the prior year (or 27% in constant currency), this was a 21% increase on the comparable pre-pandemic period, being the first half of the 2020 financial year (\$570.9 million). Net profit after tax for the first half was \$95.9 million, a 57% decline from the prior comparable period, or a 65% decline in constant currency.

Managing Director and CEO Lewis Gradon said, "Consistent with what we signalled in August, first half revenue was down on the prior corresponding period as we lapped significant COVID-19-driven demand. Compared to pre-pandemic levels, this represents solid growth."

In the Hospital product group, which includes humidification products used in respiratory, acute and surgical care, revenue for the first half was \$438.7 million. This marks a decline of 35% on the prior comparable period, or 37% in constant currency. This represents an increase of 24% on the first half of the 2020 financial year. Of total Hospital product group revenue, 87% was from the sale of consumables and 13% was from the sale of hardware.

"Customer stock levels of hospital consumables continued to reflect purchases of considerable amounts during our prior half, in preparation for an Omicron hospitalisation wave which proved less severe than originally anticipated," said Mr Gradon.

"Through the first half, there are positive signs that our hospital customers are working through their excess inventory holdings, and total group sales of our hospital consumables have increased sequentially on a month-by-month basis since May. This trend has continued in the second half to date.

"While we believe the number of hospitals which continue to be overstocked is declining, ultimately, these stocking dynamics are short term, and the fundamentals of our sales strategy remain the same. Our teams are committed to helping improve clinical practice and ensuring the hardware our customers have purchased during the pandemic is used to benefit a broader range of patients requiring respiratory support."

In the Homecare product group, which includes products used in the treatment of obstructive sleep apnea (OSA) and respiratory support in the home, revenue was \$249.9 million, a 10% increase over the prior comparable period, or 4% in constant currency. OSA masks and accessories revenue increased 16% on the prior comparable period, or 10% in constant currency.

"It has been pleasing to see a strong reception for our new Evora Full mask, which we began selling into the United States in April following 510(k) approval," said Mr Gradon. "Initial feedback from clinicians and end users has been positive, and this provides added momentum for our team working hard on a robust product pipeline."

Gross margin was 59.8%, down from 63.1% in the prior period and below the company's long-term target of 65%. Although global freight rates are seeing prices soften, legs in and out of New Zealand lag this trend, which continues to weigh on margin. The company has also been

impacted by manufacturing inefficiencies, as it carefully balances demand fluctuations while managing manufacturing throughput and higher rates of sickness-related absenteeism in the manufacturing workforce.

The company reached a number of infrastructure milestones over the half to support continued growth. This includes the announcement in September that the company had entered into a conditional agreement to purchase a 105-hectare site for an additional campus in Karaka, Auckland. This acquisition is subject to Overseas Investment Office (OIO) approval, and the company expects a response from the agency in the first half of the 2023 calendar year.

The company's directors have approved an increased interim dividend of 17.5 cents per share (H1 FY22: 17.0 cents per share). The interim dividend, carrying full New Zealand imputation credit, will be paid on 21 December 2022 with a record date of 9 December 2022.

The company is also reactivating its dividend reinvestment plan, as noted in an additional news release issued today, through which eligible shareholders can opt to invest all or part of their cash dividends in additional shares with an applicable discount of 3%. Details of this plan are available on the company website at www.fphcare.com/drp.

Looking ahead

"Our second half will be impacted by a number of factors, including:

- The rate of COVID-19 hospitalisations and the related intensity of respiratory support required;
- The severity and duration of a Northern Hemisphere flu season;
- The magnitude of RSV (respiratory syncytial virus) hospitalisation surges currently experienced in some regions; and
- The impact of ongoing hospital staffing challenges on the surgical procedure backlogs in many countries.

"Given these current uncertainties, we are not providing full-year quantitative revenue or earnings guidance at this time.

"However, we expect second half revenue for the 2023 financial year will be higher than in the first half.

"In our Hospital product group, pre-COVID-19 seasonal patterns have typically resulted in higher sales of hospital consumables in the second half compared to the first half. In the 2018 and 2019 financial years (being our most recent years that were unimpacted by COVID-19), our hospital consumable sales were 19% higher in constant currency during the second half compared to the first half. In addition, it is likely that a proportion of customers have worked through Omicron-driven consumables stock during our first half.

"In our Homecare product group, we believe the recent launch of our new Evora Full face mask, combined with improving global supply of CPAP hardware, will contribute to continued growth for the remainder of the year.

"Assuming current, slightly lower freight costs and reduced manufacturing inefficiencies, constant currency gross margin for the second half would improve from the first half by approximately 200 basis points," said Mr Gradon.

The company is now targeting constant currency operating expense growth of approximately 8% for the full year.

"We remain committed to sustainable, profitable growth," said Mr Gradon. "Our confidence in the future is unchanged, evidenced by the significant level of investment in new product development, our global sales force and our infrastructure."

Overview of key results for the first half of the 2023 financial year

- 57% decline in net profit after tax to \$95.9 million, 65% decline in constant currency.
- 23% decline in operating revenue to \$690.6 million, 27% decline in constant currency.
- 35% decline in Hospital operating revenue to \$438.7 million, 37% decline in constant currency.
- 23% decline in constant currency for new applications consumables (products used in noninvasive ventilation, Optiflow nasal high flow and surgical applications) accounting for 68% of Hospital consumables revenue.
- 10% growth in Homecare operating revenue, 4% growth in constant currency.
- Investment in R&D was 12% of revenue, or \$84.2 million.
- 3% increase in interim dividend to 17.5 cps (H1 FY22: 17.0 cps).

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company's products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

Ends

Media & Investor Contacts

Karen Knott
GM Corporate Communications
karen.knott@fphcare.co.nz
+64 (0) 21 713 911

Hayden Brown
Investor Relations Manager
hayden.brown@fphcare.co.nz
+64 (0) 27 807 8073

Authorised by Fisher & Paykel Healthcare Corporation Limited's Board of Directors.

Accompanying Documents

Attached to this news release are the following additional documents:

- Results in Brief
- Interim Report 2023
- Investor Presentation
- NZX Results Announcement
- NZX Distribution Notice

Constant Currency Information

Constant currency information included within this news release is non-GAAP financial information, as defined by the NZ Financial Markets Authority, and has been provided to assist users of financial information to better understand and track the company's comparative financial performance without the impacts of spot foreign currency fluctuations and hedging results and has been prepared on a consistent basis each year. A constant currency analysis is included on page 14 of the company's Interim Report 2023, and the company's constant currency framework can be found on the company's website at www.fphcare.com/ccf.

Half Year Results Conference Call

Fisher & Paykel Healthcare will host a conference call on Tuesday, 29 November 2022 to discuss the half year result. The conference call is scheduled to begin at 10:00am NZDT, 8:00am AEDT (4:00pm USEST, Monday, 28 November) and will be webcast.

To listen to the webcast, access the company's website at www.fphcare.com/investor. An online archive of the event will be available approximately two hours after the webcast and will remain on the site for two weeks.

To listen and participate in the conference call via phone, please register via 'GlobalMeet' by clicking this [link](#). Once registered, click 'Call Me' and you will receive a phone call connecting you through to the conference line.

Results in Brief

	Six Months Ended 30 Sep 21 NZ\$M (except as otherwise stated)	Six Months Ended 30 Sep 22 NZ\$M (except as otherwise stated)	% Change (Reported)	% Change (Constant Currency ¹)
FINANCIAL PERFORMANCE				
Total operating revenue	900.0	690.6	-23%	-27%
Cost of sales	(332.3)	(277.4)	-17%	-16%
Gross profit	567.7	413.2	-27%	-33%
Gross margin	63.1%	59.8%	-325bps	-533bps
Selling, general and administrative expenses	(189.6)	(202.3)	+7%	-%
Research and development expenses	(75.7)	(84.2)	+11%	+11%
R&D percentage of operating revenue	8.4%	12.2%	+378bps	+445bps
Total operating expenses	(265.3)	(286.5)	+8%	+3%
Operating profit before financing costs	302.4	126.7	-58%	-67%
Operating margin	33.6%	18.3%	-1526bps	-1770bps
Net financing income (expense)	(1.3)	(12.4)	+854%	-125%
Profit before tax	301.1	114.3	-62%	-67%
Tax expense	(79.3)	(18.4)	-77%	-74%
Profit after tax	221.8	95.9	-57%	-65%
Effective tax rate	26.3%	16.1%		
Effective tax rate excluding R&D tax credit	28.8%	22.7%		
Revenue by Region:				
North America	329.8	289.5	-12%	
Europe	232.0	188.0	-19%	
Asia Pacific	267.2	174.2	-35%	
Other	71.0	38.9	-45%	
Total	900.0	690.6	-23%	
Revenue by Product Group:				
Hospital	670.2	438.7	-35%	
Homecare	226.9	249.9	+10%	
Core products sub-total	897.1	688.6	-23%	
Distributed and other	2.9	2.0	-32%	
Total	900.0	690.6	-23%	
FINANCIAL POSITION				
	As at 31 Mar 22 NZ\$M (except as otherwise stated)	As at 30 Sep 22 NZ\$M (except as otherwise stated)		
Tangible assets	1,936.6	1,837.8	-5%	
Intangible assets ²	170.4	256.7	+51%	
Total assets	2,107.0	2,094.5	-1%	
Total liabilities	(427.3)	(616.1)	+44%	
Shareholders' equity	1,679.7	1,478.4	-12%	
Gearing	-16.3%	2.7%	+19%	
Net tangible asset backing (cents per share)	261	211	-19%	

¹ Constant currency (CC) removes the impact of exchange rate movements. This approach is used to assess the Group's underlying comparative financial performance without any impact from changes in foreign exchange rates. The company's constant currency framework can be found on the company's website at www.fphcare.com/ccf. The reconciliation to reported results is included within the Financial Commentary section of the Interim Report.

² Includes Intangible and deferred tax assets.

Results in Brief (continued)

	Six Months Ended 30 Sep 21 NZ\$M (except as otherwise stated)	Six Months Ended 30 Sep 22 NZ\$M (except as otherwise stated)	% Change
CASH FLOWS			
Net cash flow from operating activities	127.5	1.9	-99%
Net cash flow (used in) investing activities	13.8	75.2	+445%
Net cash flow (used in) financing activities	(131.9)	(107.5)	-19%
SHARES OUTSTANDING			
Weighted average basic shares outstanding	576,615,929	577,490,656	
Weighted average diluted shares outstanding	579,772,363	580,504,570	
Basic shares outstanding at period end	577,131,310	577,663,664	
DIVIDENDS AND EARNINGS PER SHARE			
Dividends per share (cents) – declared	17.0	17.5	+3%
Basic earnings per share (cents)	38.5	16.6	-57%

COMMITMENT

Contents

OVERVIEW OF KEY FINANCIAL RESULTS	2
HALF YEAR BUSINESS UPDATES	3
PRODUCT GROUP OVERVIEW	4
HALF YEAR REVIEW	6
FINANCIAL COMMENTARY	11
FINANCIAL STATEMENTS	15
NOTES TO THE FINANCIAL STATEMENTS	19
DIRECTORY	24

Constant currency information contained within this report is non-conforming financial information, as defined by the NZ FMA and has been provided to assist users of financial information to better understand and assess the company's financial performance without the impacts of spot financial currency fluctuations and hedging results, and has been prepared on a consistent basis each financial year. A reconciliation between reported results and constant currency results is available on page 14 of this report. The company's constant currency framework can be found on our website at www.fphcare.com/ccf.

This report is dated 28 November 2022 and is signed on behalf of Fisher & Paykel Healthcare Corporation Limited by Scott St John, Board Chair and Lewis Gradon, Managing Director and Chief Executive Officer.



SCOTT ST JOHN
BOARD CHAIR



LEWIS GRADON
MANAGING DIRECTOR AND
CHIEF EXECUTIVE OFFICER

commitment

/kə'mɪtm(ə)nt/

The state or quality of being
dedicated to a cause or activity.



HALF YEAR

Overview of key financial results

OPERATING REVENUE

\$690.6M

▼ 23% | 1H FY22 (\$900.0M)

NET PROFIT AFTER TAX

\$95.9M

▼ 57% | 1H FY22 (\$221.8M)

GROSS MARGIN

59.8%INTERIM DIVIDEND
FULLY IMPUTED**17.5CPS**

▲ 3% | 1H FY22 (17CPS)

SPEND ON R&D

\$84.2M

12% OF OPERATING REVENUE

HOSPITAL REVENUE

\$438.7M

▼ 35% | 1H FY22 (670.2M)

OSA MASKS AND ACCESSORIES
REVENUE GROWTH**↑10%**


(CONSTANT CURRENCY)

HALF YEAR business updates

REVENUE BY REGION 6 MONTHS TO 30 SEPTEMBER 2022



REVENUE BY PRODUCT GROUP 6 MONTHS TO 30 SEPTEMBER 2022



CONTINUED to build out our anesthesia sales force in Europe and North America.

ENTERED into conditional agreement for land to construct our second New Zealand campus.

ADVANCED construction of our fifth facility at our existing New Zealand campus.

COMPLETED the construction of our third manufacturing facility in Tijuana.

PROGRESSED the roll-out of our new technology, including Airvo™ 3, Optiflow™ Switch and Evora™ Full.

PRESENTED with four social responsibly awards by the Association of Human Resources in Tijuana.

APPOINTED Cather Simpson to the Board of Directors.

Product group overview

Our business is structured in two parts: Hospital and Homecare.

Our Hospital product group includes products used in invasive ventilation, noninvasive ventilation, nasal high flow, and laparoscopic and open surgery. Not only do these products help healthcare providers improve patient outcomes, they often deliver economic benefits as well, by reducing the need to escalate care and shortening patient stays in hospital.

PRODUCT FEATURED:



Hospital



64%

OF OPERATING REVENUE

OPERATING REVENUE

\$438.7M

NEW APPLICATIONS CONSUMABLES AS A
% OF HOSPITAL CONSUMABLES REVENUE

68%

The Homecare product group includes devices and systems used to treat obstructive sleep apnea (OSA) and provide respiratory support in the home. These include our CPAP therapy masks as well as flow generators, interfaces, and data management technologies.

PRODUCT FEATURED:

F&P Evora Full

Homecare



36%

OF OPERATING REVENUE

OPERATING REVENUE

\$249.9M

OSA MASKS AND ACCESSORIES
CONSTANT CURRENCY REVENUE

↑10%

Half year review

The word 'commitment' has long held significant meaning for us. One of our five company values, it has resonated strongly in recent months as we reflect on the efforts required through the pandemic period. It resonates further still as we move forward, describing the focus on our long-term aims and the discipline required to achieve them.

Getting our life-preserving product out to patients was paramount during the peak of the pandemic – this came first, and everything else flowed from that. As we said back in May at our full-year result, we did not let these events divert us from our long-term course, and that is worth repeating now. We remain committed to sustainable, profitable growth, and our confidence in the future is unchanged. We are investing significantly in that future and, as we do so, our people are focused on identifying the right near-term actions that strengthen us for the long term.

FINANCIAL RESULTS

As we said in our trading update in August, revenue was down on the prior period but elevated compared with pre-pandemic levels. For the six months ended 30 September 2022, total operating revenue was \$690.6 million, 23 per cent below the same period last year, or 27 per cent in constant currency. This represents a 21 per cent increase on the first half of the 2020 financial year (\$570.9 million). Net profit after tax was \$95.9 million, 57 per cent below the same period last year, or 65 per cent in constant currency.



SCOTT ST JOHN
Board Chair



LEWIS GRADON
Managing Director and
Chief Executive Officer

Our Hospital product group comprised 64 per cent of revenue at \$438.7 million, representing a 35 per cent decline on the prior year, or 37 per cent in constant currency. This marks a 24 per cent increase compared to the comparable pre-pandemic period, being the first half of the 2020 year (\$353.6 million). Hospital consumables sales in constant currency were down 19 per cent on the prior year, but up 25 per cent on the first half of 2020. We believe customer stock levels have been elevated during the first half, reflecting hospital purchases of considerable amounts of product in preparation for an Omicron wave which, for the most part, proved less severe than originally anticipated. Ultimately, we see these stocking dynamics as short-term, and the fundamentals of our sales strategy remain the same. Our teams are committed to helping improve clinical practice and ensuring the hardware our customers have purchased is used to benefit a broader range of patients requiring respiratory support.

Our Homecare product group delivered revenue of \$249.9 million, representing growth of 10 per cent on the first half last year or 4 per cent in constant currency. Pleasingly, our OSA masks and accessories revenue increased 10 per cent in constant currency. The early reception to our new Evora™ Full mask has been very favourable. We received 510(k) approval in the United States in April and have since seen strong sales volumes and positive user feedback. This adds to the momentum for our OSA team who are working hard on a robust product pipeline.



UNLOCKING FUTURE GROWTH: Our proposed Karaka campus

We have repeatedly signalled the importance of long-term infrastructure planning to help us deliver on our sustainable, profitable growth strategy and our aspirations of doubling constant currency revenue every five to six years. To take advantage of the opportunities ahead of us, we need more space, and we took an important step in securing this during the first half.

In September, we entered into a conditional agreement, subject to approval by the Overseas Investment Office, to purchase a 105-hectare site for an additional New Zealand campus in Karaka, Auckland.

At more than double the size of our current site, the Karaka campus would afford us with significant room to grow. Should we be successful with our OIO application, development of the new campus will occur gradually over a 20 to 30-year period, with a focus on earthworks and core infrastructure over the next five years.

These plans reaffirm our confidence in our long-term opportunities and demonstrate our strong commitment to R&D and manufacturing in New Zealand.

Gross margin for the half was 59.8 per cent, down from 63.1 per cent in the prior period and below our long-term target of 65 per cent. Elevated freight rates remain a factor – major global routes are seeing prices soften, though legs in and out of New Zealand remain behind this curve, with prices taking longer to normalise. The half has also seen us manage through manufacturing inefficiencies, as we have been carefully balancing demand fluctuations with manufacturing throughput and higher rates of absenteeism in our manufacturing workforce due to sickness.

STRATEGIC PROGRESS

In May, we introduced our latest anesthesia products – Optiflow Switch™ and Optiflow Trace™ – which provide even more compelling reasons to use F&P's Optiflow technology during general anesthesia and procedural sedation. Adding to our anesthesia salesforce has been a clear priority in the months since and will remain so going forward. Feedback from anesthesiologists continues to be positive and gives us confidence in both the benefit to patients and the size of the market opportunity.

We are continuing with a controlled market release of our new Airvo™ 3 nasal high flow device in Australasia while seeking regulatory clearances further afield. We believe the new device is an attractive proposition, with a closed loop system for targeted oxygen delivery and an integrated battery to allow for more portability through the hospital.

At our first half result last year, we signalled plans to continue to invest in our infrastructure to support growth. We have made significant strides since, including our announcement in September that we have entered into a conditional agreement to purchase a 105-hectare site for an additional New Zealand campus in Karaka, Auckland. This acquisition is subject to Overseas Investment Office (OIO) approval, and we expect a response from the agency in the first half of 2023. If successful, development of this new campus will occur over a 20 to 30-year period.

Elsewhere, we saw the completion of our third building in Tijuana, which adds an additional 50 per cent of space to our manufacturing footprint in Mexico. We are also continuing with earthworks for the fifth building on our existing New Zealand campus in addition to a multi-storey carpark.

We also indicated that we were investigating options for an additional offshore manufacturing location, and we can now report that we have entered into a lease agreement for a facility in Guangzhou, China. Our presence in the city dates back almost 20 years, where we have a well-entrenched sales operation serving the mainland. The new facility is aligned with our distributed manufacturing strategy, and our intent is to manufacture a select range of products to service local markets.

In May, we introduced our latest anesthesia products – Optiflow Switch™ and Optiflow Trace™ – which provide even more compelling reasons to use F&P's Optiflow technology during general anesthesia and procedural sedation.

ENVIRONMENTAL AND SOCIAL RESPONSIBILITY

Earlier this year we articulated our intentions in the form of a new Environmental and Social Responsibility policy, making it clear that our aim is to have a lasting positive impact on society and the environment. This statement of intent guides our newly formed governance group, which is comprised of subject matter experts from around the business working together to identify improvements and step-changes we can make as a business globally. It is good to see this group build momentum.

We have again achieved inclusion in the Dow Jones Sustainability Indices for Asia Pacific and Australia in addition to the FTSE4Good Index, and were recently nominated as a finalist in the Sustainable Business Leadership category as part of the Deloitte Top 200 awards, which celebrate outstanding performance among New Zealand's largest companies.

BOARD UPDATE

We were pleased to welcome Cather Simpson, PhD, as a non-executive director in June, bringing our board up to full strength in advance of Geraldine McBride's farewell at the close of our Annual Shareholders' Meeting in August. Cather is a valuable addition, bringing extensive experience commercialising scientific research.

DIVIDEND

The Board of Directors has approved an interim dividend of 17.5 cents per share for the six months to 30 September 2022, marking an increase of 3 per cent from the first half of the prior financial year. The dividend will be paid on 21 December 2022 with a record date of 9 December. This year, we are re-activating our dividend reinvestment plan through which eligible shareholders can opt to invest all or part of their cash dividends in additional shares, with an applicable 3 per cent discount. Details of this plan are available on our website.

PROFIT SHARE

Our people remain our strength and have once again responded admirably during a challenging year. To recognise their efforts, the Board has approved a discretionary profit-sharing payment of \$4 million for employees who have worked for the company for a qualifying period.

THANK YOU

Again, we want to recognise the ongoing efforts of those right across the healthcare sector. While it has been pleasing to see a normalisation of sorts after the peak pandemic period, we acknowledge conditions remain challenging. With travel restrictions relaxing, our global teams have relished re-connecting with our customers, suppliers and clinical partners at events and healthcare facilities throughout the world. This has reinforced how our business is a relational one, and we look forward to more of this.

We also wish to acknowledge the unique challenges over the last six months for our people as a combination of seasonal illnesses and COVID-19 have meant extended periods of home isolation and continued disruption to work environments for many. Thanks to all of you for your work in oftentimes trying circumstances. And a final word of thanks to our shareholders: your continued support makes all this possible.



Scott St John
Board Chair



Lewis Gradon
Managing Director and
Chief Executive Officer

Financial report



Financial commentary

INCOME STATEMENTS

For the six months ended 30 September	2021 NZ\$M	2022 NZ\$M	Change Reported %	Change CC ¹ %
Operating revenue	900.0	690.6	-23	-27
Gross profit	567.7	413.2	-27	-33
Gross margin	63.1%	59.8%	-325bps	-533bps
SG&A expenses	(189.6)	(202.3)	+7	-
R&D expenses	(75.7)	(84.2)	+11	+11
Total operating expenses	(265.3)	(286.5)	+8	+3
Operating profit	302.4	126.7	-58	-67
Operating margin	33.6%	18.3%	-1,526bps	-1,770bps
Net financing (expense)	(1.3)	(12.4)	+854	-125
Profit before tax	301.1	114.3	-62	-67
Tax expense	(79.3)	(18.4)	-77	-74
Profit after tax	221.8	95.9	-57	-65

¹ Constant currency (CC) removes the impact of exchange rate movements. This approach is used to assess the Group's underlying comparative financial performance without any impact from changes in foreign exchange rates. See further details on page 14.

Total profit after tax for the period was \$95.9 million, a 57% decline from the same period last year, or 65% in constant currency.

Revenue

Operating revenue was \$690.6 million, a 23% decline from the prior comparable period (PCP) or 27% in constant currency. Hospital revenue decreased 37% in constant currency as we lapped significant COVID-19 driven demand last year and apparent elevated customer inventory levels during this period. Homecare revenue grew 4% in constant currency.

Gross margin

Gross margin at 59.8% decreased by 533 basis points in constant currency from the same period last year. Continued elevated freight costs and air freight utilisation this period impacted constant currency gross margin by approximately 290 basis points compared to pre-COVID-19 rates. Manufacturing inefficiencies were also experienced this year as we balance demand fluctuations with manufacturing throughput.

Operating expenses

Operating expenses increased 8% (3% in constant currency) to \$286.5 million, reflecting ongoing expenditure to support global sales growth and development of our product pipeline.

R&D spend of \$84.2 million grew 11% reflecting underlying growth and the timing of R&D and clinical projects. Over the long term we plan for R&D spend to grow in line with constant currency revenue growth.

Financing expenses


The net financing expense increase reflects the exchange losses on the revaluation of foreign currency interest bearing liabilities. Excluding the impact of foreign currency revaluations, net financing expense was in line with the prior period.

Tax

Our effective tax rate for the period was 16.1%, down from 26.3% in the prior period reflecting foreign currency translation gains that are non-taxable. The R&D tax credit this period of \$7.6 million (Sep 2021: \$7.4 million) represents the estimated eligible R&D expenditure incurred during the period. Excluding the benefit of the R&D tax credit the effective tax rate was 22.7% (Sep 2021: 28.8%).

FOREIGN CURRENCY IMPACTS

The Group is exposed to movements in foreign exchange rates, with approximately 99% of operating revenue generated in currencies other than NZD as shown below.



Approximately 60% of COGS and over 50% of operating expenses are in currencies other than NZD.

Net profit after tax was increased by \$6.1 million compared to the prior period due to the impact of foreign currency. During the period since 31 March 2022, the NZD weakened significantly against major currencies.

The effect of balance sheet translations for the period resulted in an increase in operating revenue of \$18.6 million (Sep 2021: \$2.5 million increase) and an increase in profit after tax of \$0.8 million (Sep 2021: \$2.4 million increase). The hedging programme contributed a pre-tax gain of \$0.5 million (Sep 2021: \$21.1 million gain).

The average daily spot rate and the average conversion exchange rate (i.e. the accounting rate, incorporating the benefit of forward exchange contracts in respect of the relevant financial year) of the main foreign currency exposures for the reported periods are set out in the table below.

Six months ended 30 September	Average daily spot rate		Average conversion exchange rate	
	2021	2022	2021	2022
USD	0.7077	0.6312	0.6769	0.6700
EUR	0.5938	0.6095	0.5594	0.5445

Foreign exchange hedging position

In line with our hedging programme, additional hedges have been added for future years, in particular for financial years 2025 to 2031. The hedging position for our main currency exposures as at 10 November 2022 is:

Year to 31 March	2023	2024	2025	2026	2027	2028	2029 – 2031*
USD % cover of expected exposure	90%	80%	65%	55%	50%	25%	5%
USD average rate of cover	0.667	0.658	0.622	0.608	0.596	0.585	0.526
EUR % cover of expected exposure	85%	60%	50%	30%	20%	10%	–
EUR average rate of cover	0.542	0.536	0.521	0.529	0.517	0.521	–

* 2029 – 2031 shows average % cover of expected exposure and rate of cover for the three-year period

Hedging cover has been rounded to the nearest 5%.

CASH FLOWS

The full statement of cash flows is provided on page 18.

	2021 NZ\$M	2022 NZ\$M	Change NZ\$M
For the six months ended 30 September			
Operating profit before financing costs	302.4	126.7	(175.7)
Plus depreciation and amortisation	46.0	50.5	4.5
Change in working capital and other	(31.2)	(97.2)	(66.0)
Net interest paid	(1.7)	(2.0)	(0.3)
Net income tax paid	(188.0)	(76.1)	111.9
Operating cash flows	127.5	1.9	(125.6)
Lease repayments	(6.6)	(6.7)	(0.1)
Purchase of land and buildings	(14.7)	(64.0)	(49.3)
Purchase of plant and equipment	(50.1)	(48.0)	2.1
Purchase of intangible assets	(16.5)	(12.8)	3.7
Free cash flows*	39.6	(129.6)	(169.2)
Dividends paid	(126.8)	(129.9)	(3.1)

* Free cash flows include lease liability repayments following the adoption of NZ IFRS 16.

Operating cash flows

Cash flows from operations for the period decreased to \$1.9 million (Sep 2021: \$127.5 million). Working capital continued to be impacted by increases in raw materials and finished goods inventories. We have been working to balance demand fluctuations with manufacturing throughput and continuing supply chain disruption.

Capital expenditure

During the period, \$124.8 million was spent on capital expenditure (excluding leased assets), including earthworks and constructions costs across the East Tamaki and Tijuana campuses. Spending also includes a \$27.5 million deposit to acquire land for a second New Zealand campus. This purchase is contingent on receiving Overseas Investment Office (OIO) consent on terms and conditions acceptable to the Company and is recorded in other receivables on the balance sheet. We continue to invest in production tooling and equipment additions.

Dividends

Dividends paid of \$129.9 million were 2% higher than the prior period.

BALANCE SHEET

As at	31 March 2022 NZ\$M	30 September 2022 NZ\$M	Change NZ\$M
Trade receivables	142.8	153.8	11.0
Inventories	358.9	398.4	39.5
Less trade and other payables*	(132.4)	(103.2)	29.2
Working capital	369.3	449.0	79.7
Property, plant and equipment**	957.8	1,044.8	87.0
Intangible assets	86.8	88.3	1.5
Lease liabilities	(36.0)	(55.3)	(19.3)
Other net assets (liabilities)	80.2	(5.8)	(86.0)
Net cash (debt)	221.6	(42.6)	(264.2)
Net assets	1,679.7	1,478.4	(201.3)

* Trade and other payables exclude all non-current payables and all employee entitlements and provisions

** Property, plant and equipment includes lease assets recognised

Trade receivables increase to 30 September 2022 reflects balance sheet translation of foreign currency receivable balances. Our debtor days were within the normal range at 42 days (March 2022: 41 days). Inventories balances have increased both in raw materials and finished goods. Trade and other payables reduction includes timing associated with key capital projects and payment of suppliers.

Property, plant and equipment increased by \$87.0 million in the period. Additions of \$105.2 million and foreign currency translations were offset by \$39.2 million of depreciation. Intangible assets increased by \$1.5 million, primarily due to patent acquisition costs. Included in intangible assets is ERP system capital spending with our global SAP rollout continuing over the next two to three years.

Other net assets/liabilities movements included a change in derivative financial instruments from a net asset of \$140.7 million at 31 March 2022 to a net liability of \$110.8 million at 30 September 2022. This is due to the currency volatility during the period, with the corresponding offset in the cash flow hedge reserve. All currency derivatives continued to be effective hedges. Net tax assets increased by \$127.1 million during the period, primarily reflecting the change in the net derivative financial instruments balances.

Net cash and debt facilities

As at	31 March 2022 NZ\$M	30 September 2022 NZ\$M	Change NZ\$M
Loans and borrowings			
– Current	–	(33.4)	(33.4)
– Non Current	(63.0)	(70.0)	(7.0)
Bank overdrafts	(5.3)	(9.0)	(3.7)
Total interest-bearing liabilities*	(68.3)	(112.4)	(44.1)
Cash and cash equivalents	89.9	69.8	(20.1)
Short-term investments	200.0	–	(200.0)
Total cash and investments	289.9	69.8	(220.1)
Net cash (debt)	221.6	(42.6)	(264.2)
Gearing	-16.3%	2.7%	19.0%
Undrawn committed debt facilities	184.5	156.6	(27.9)
Undrawn uncommitted debt and overdraft facilities	38.3	85.5	47.2

* Excluding lease liabilities

The average maturity of loans and borrowings of \$103.4 million was 1.5 years and the currency split was 68% USD; 27% NZD; 3% Australian dollars; and 2% Canadian dollars.

Within the next 12 months, two facilities totalling \$70 million will expire. The Company is in the process of negotiating additional committed borrowing facilities, to be in place prior to 31 March 2023.

Cash and cash equivalents, were \$69.8 million at 30 September 2022. This balance, operating cash generated in the second half of FY23 and additional borrowings, will fund the payment of the interim dividend, ongoing capital expenditure including building projects in East Tamaki and the purchase of land for a second NZ Campus, if OIO consent is granted on terms and conditions acceptable to the Company.

Gearing¹

At 30 September 2022 the Group had gearing of 2.7%. Gearing was inside the target range of -5% to +5%.

NOTES – CONSTANT CURRENCY

Constant currency analysis is non-Generally Accepted Accounting Practice (GAAP) financial information, that is not prepared in accordance with New Zealand Equivalents to International Financial Reporting Standards (NZ IFRS). Constant currency information has been provided to assist users of financial information to better understand and assess the Group's financial performance without the impacts of foreign currency fluctuations, including hedging results.

Constant currency financial information is prepared each month to enable the Board and management to monitor and assess the Group's underlying comparative financial performance without any distortion from changes in foreign exchange rates. Constant currency information is prepared on a consistent basis for reported periods restated into NZD based on "constant" exchange rates, typically the budgeted exchange rates for the current year. This information excludes the impact of movements in foreign exchange rates, hedging results and balance sheet translations.

The Group's constant currency framework can be found on the company's website at www.fphcare.com/ccf. PwC perform assurance procedures over the constant currency information.

RECONCILIATION OF CONSTANT CURRENCY TO REPORTED PROFIT AFTER TAX

	2021 NZ\$M	2022 NZ\$M	Change NZ\$M
For the six months ended 30 September			
Profit after tax (constant currency)	204.1	72.1	(132.0)
Spot exchange rate effect	0.1	22.6	22.5
Foreign exchange hedging result	15.2	0.4	(14.8)
Balance sheet revaluation	2.4	0.8	(1.6)
Profit after tax (reported)	221.8	95.9	(125.9)

The significant exchange rates used in the constant currency analysis, being the budget exchange rates for the year ended 31 March 2023, are USD 0.69, EUR 0.61, AUD 0.93, GBP 0.51, CAD 0.86, JPY 79, MXN 14.0, CNY 4.3, KRW 820, SEK 6.6 and INR 51.

¹ Net interest-bearing debt (debt less cash and cash equivalents and short-term investments) to net interest-bearing debt and equity (less hedging reserves). Net interest-bearing debt excludes lease liabilities.

Financial statements

CONSOLIDATED INCOME STATEMENT

For the six months ended 30 September 2022

	Notes	Unaudited 2021 NZ\$M	Unaudited 2022 NZ\$M
Operating revenue	3	900.0	690.6
Cost of sales		(332.3)	(277.4)
Gross profit		567.7	413.2
Selling, general and administrative expenses		(189.6)	(202.3)
Research and development expenses		(75.7)	(84.2)
Total operating expenses		(265.3)	(286.5)
Operating profit		302.4	126.7
Financing income		1.2	1.5
Financing expense		(2.4)	(1.2)
Exchange gain / (loss) on foreign currency interest-bearing liabilities		(0.1)	(12.7)
Net financing income / (expense)		(1.3)	(12.4)
Profit before tax	4	301.1	114.3
Tax expense		(79.3)	(18.4)
Profit after tax		221.8	95.9
Basic earnings per share		38.5 cps	16.6 cps
Diluted earnings per share		38.3 cps	16.5 cps

The accompanying notes form an integral part of the financial statements.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 September 2022

	Unaudited 2021 NZ\$M	Unaudited 2022 NZ\$M
Profit after tax	221.8	95.9
Other comprehensive income		
<i>Items that may be reclassified to profit or loss</i>		
Foreign currency translation reserve		
Exchange differences on translation of foreign operations	1.2	8.8
Hedging reserves		
Changes in fair value in hedging reserves	(22.2)	(248.6)
Transfers to profit before tax from cash flow hedge reserve	(21.0)	(0.6)
Tax on above reserve movements	12.1	69.8
Other comprehensive income, net of tax	(29.9)	(170.6)
Total comprehensive income	191.9	(74.7)

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 September 2022

	Notes	Share capital NZ\$M	Retained earnings NZ\$M	Reserves NZ\$M	Total equity NZ\$M
Balance at 31 March 2021 (audited)		249.1	1,029.2	242.6	1,520.9
Total comprehensive income		-	221.8	(29.9)	191.9
Dividends paid	9	-	(126.8)	-	(126.8)
Issue of share capital under employee share plans		6.4	-	-	6.4
Movement in share based payments reserve		-	-	(1.6)	(1.6)
Balance at 30 September 2021 (unaudited)		255.5	1,124.2	211.1	1,590.8
Balance at 31 March 2022 (audited)		261.2	1,181.2	237.3	1,679.7
Total comprehensive income		-	95.9	(170.6)	(74.7)
Dividends paid	9	-	(129.9)	-	(129.9)
Issue of share capital under employee share plans		3.7	-	-	3.7
Movement in share based payments reserve		-	-	(0.4)	(0.4)
Balance at 30 September 2022 (unaudited)		264.9	1,147.2	66.3	1,478.4

The accompanying notes form an integral part of the financial statements.

CONSOLIDATED BALANCE SHEET

As at 30 September 2022

	Notes	Audited 31 March 2022 NZ\$M	Unaudited 30 September 2022 NZ\$M
ASSETS			
Current assets			
Cash and cash equivalents		89.9	69.8
Short-term investments		200.0	-
Trade and other receivables		174.4	198.2
Inventories		358.9	398.4
Derivative financial instruments	5	56.4	33.0
Tax receivable		8.3	24.4
Total current assets		887.9	723.8
Non-current assets			
Derivative financial instruments	5	87.7	39.7
Other receivables		3.2	29.5
Property, plant and equipment		957.8	1,044.8
Intangible assets		86.8	88.3
Deferred tax assets		83.6	168.4
Total assets		2,107.0	2,094.5
LIABILITIES			
Current liabilities			
Borrowings		5.3	42.4
Lease liabilities		11.7	14.9
Trade and other payables		226.2	204.6
Provisions		26.3	25.3
Tax payable		31.9	5.7
Derivative financial instruments	5	2.5	75.7
Total current liabilities		303.9	368.6

	Notes	Audited 31 March 2022 NZ\$M	Unaudited 30 September 2022 NZ\$M
LIABILITIES			
Non-current liabilities			
Borrowings		63.0	70.0
Lease liabilities		24.3	40.4
Provisions		11.1	7.7
Other payables		24.1	21.6
Derivative financial instruments	5	0.9	107.8
Total liabilities		427.3	616.1
EQUITY			
Share capital		261.2	264.9
Retained earnings		1,181.2	1,147.2
Reserves		237.3	66.3
Total equity		1,679.7	1,478.4
Total liabilities and equity		2,107.0	2,094.5

The accompanying notes form an integral part of the financial statements.

On behalf of the Board
28 November 2022

Scott St John
Board Chair

Lewis Gradon
Managing Director and Chief Executive Officer

CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 September 2022

	Unaudited 2021 NZ\$M	Unaudited 2022 NZ\$M
CASH FLOWS FROM OPERATING ACTIVITIES		
Receipts from customers	883.1	675.4
Interest received	1.0	2.0
Payments to suppliers and employees	(565.9)	(595.4)
Tax paid	(188.0)	(76.1)
Interest paid	(1.9)	(2.9)
Lease interest paid	(0.8)	(1.1)
Net cash flows from operating activities	127.5	1.9
CASH FLOWS FROM INVESTING ACTIVITIES		
Net short-term investments	95.1	200.0
Purchases of property, plant and equipment	(64.8)	(112.0)
Purchases of intangible assets	(16.5)	(12.8)
Net cash flows from investing activities	13.8	75.2
CASH FLOWS FROM FINANCING ACTIVITIES		
Issue of share capital under employee share plans	1.5	1.6
New borrowings	-	27.5
Lease liability payments	(6.6)	(6.7)
Dividends paid	(126.8)	(129.9)
Net cash flows from financing activities	(131.9)	(107.5)
Net increase / (decrease) in cash	9.4	(30.4)
Opening cash	85.4	84.6
Effect of foreign exchange rates	(0.4)	6.6
Closing cash	94.4	60.8
RECONCILIATION OF CLOSING CASH		
Cash and cash equivalents	103.2	69.8
Bank overdrafts	(8.8)	(9.0)
Closing cash	94.4	60.8

	Unaudited 2021 NZ\$M	Unaudited 2022 NZ\$M
CASH FLOW RECONCILIATION		
Profit after tax	221.8	95.9
Add (deduct) non-cash items:		
Depreciation - right-of-use assets	6.7	7.7
Depreciation and amortisation - other assets	39.3	42.8
Share based payments	3.7	4.3
Movement in provisions	10.4	(4.4)
Movement in deferred tax assets / liabilities	(11.7)	(17.5)
Movement in net tax payables	(107.2)	(41.9)
Foreign currency translation	1.0	1.2
Other non-cash items	(0.3)	(1.9)
	(58.1)	(9.7)
Net working capital movements:		
Trade and other receivables	(8.4)	(22.5)
Inventories	(21.3)	(39.5)
Trade and other payables	(6.5)	(22.3)
	(36.2)	(84.3)
Net cash flows from operating activities	127.5	1.9

The accompanying notes form an integral part of the financial statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 September 2022

1. GENERAL INFORMATION

Reporting entity

Fisher & Paykel Healthcare Corporation Limited (the “Company” or “Parent”) together with its subsidiaries (the “Group”) is a leading designer, manufacturer and marketer of medical device products and systems for use in both hospital and homecare settings. Products are sold in over 120 countries worldwide. The Company is a limited liability company incorporated and domiciled in New Zealand.

Statement of compliance

The Company is registered under the Companies Act 1993 and is an FMC reporting entity under Part 7 of the Financial Markets Conduct Act 2013. The Company is also listed on the New Zealand Stock Exchange (NZX) and the Australian Securities Exchange (ASX).

Basis of preparation

These consolidated financial statements for the six months ended 30 September 2022 have been prepared in accordance with New Zealand Generally Accepted Accounting Practice (NZ GAAP). They comply with New Zealand Equivalent to International Accounting Standard 34: Interim Financial Reporting (NZ IAS 34) and International Accounting Standard 34: Interim Financial Reporting (IAS 34). The Company and Group are designated as profit-oriented entities for financial reporting purposes.

These consolidated financial statements do not include all of the notes normally included in an annual financial report. Accordingly, this report should be read in conjunction with the audited consolidated financial statements for the year ended 31 March 2022.

Presentation currency

These consolidated financial statements are presented in New Zealand dollars (NZD) to the nearest hundred thousand dollars unless otherwise stated.

Accounting policies

All accounting policies have been applied on a basis consistent with those used and described in the audited consolidated financial statements for the year ended 31 March 2022.

2. SIGNIFICANT TRANSACTIONS AND EVENTS FOR THE CURRENT PERIOD

The following significant transactions and events affected the financial performance and financial position of the Group for the six month period ended 30 September 2022:

COVID-19

In March 2020, the World Health Organisation declared the outbreak of COVID-19 as a pandemic. Since the outbreak of COVID-19, the Company's focus has been on manufacturing and supplying products that are directly involved in treating patients with COVID-19. The Company has experienced significant volatility in demand for its products over the last few years.

Management have assessed the impact of COVID-19 on all aspects of the balance sheet. Specifically, the carrying value of receivables, inventory and warranty exposure were considered, with provisioning reflecting management's best estimate of the impact based on information available at the time of preparing these financial statements. There has been no material impact on the balance sheet.

Foreign currency

As a result of currency volatility during this period, the liability relating to the Group's portfolio of derivatives has increased, with the corresponding offset in the cash flow hedge reserve.

Capital expenditure

During the period, a member of the Group, Fisher & Paykel Healthcare Properties Limited (**FPH Properties**), entered into a conditional agreement to purchase 105 hectares of land in Karaka for a second New Zealand campus for \$275 million. The purchase is conditional on Overseas Investment Office (OIO) consent being granted on terms and conditions that are satisfactory to FPH Properties. A deposit of \$27.5 million was paid in September 2022 and recognised in other receivables. Subject to OIO consent being granted on terms and conditions that are satisfactory to FPH Properties, \$189.5 million is expected to be paid in the first half of FY24. An additional \$43 million and \$15 million will be payable in FY26 and FY27 respectively. Additional borrowings will be used to fund the purchase.

In June 2022, a building construction contract was signed for a car park building on our East Tamaki, New Zealand campus. Capital commitments at 30 September 2022 include \$63.9 million related to this project. To date, spending on this project totals \$9.4 million. The car park is expected to be operational in 2024.

Earthworks continue for the construction of a fifth building on our East Tamaki site. To date, spending on this project totals \$17.3 million.

Share capital

During the six months ended 30 September 2022, the Group issued 257,786 shares under employee equity plans.

Funding

The Company had total available committed debt funding of \$260 million as at 30 September 2022, of which approximately \$157 million was undrawn. As at 30 September 2022, the weighted average maturity of committed borrowing facilities was 1.6 years.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

3. OPERATING REVENUE AND SEGMENTAL INFORMATION

	Unaudited 2021 NZ\$M	Unaudited 2022 NZ\$M
For the six months ended 30 September		
Sales Revenue	879.6	694.5
Foreign exchange (loss) / gain on hedged sales	20.4	(3.9)
Total operating revenue	900.0	690.6
Revenue by product group		
Hospital products	670.2	438.7
Homecare products	226.9	249.9
	897.1	688.6
Distributed and other products	2.9	2.0
Total operating revenue	900.0	690.6
Revenue after hedging by geographical location of customer:		
North America	329.8	289.5
Europe	232.0	188.0
Asia Pacific	267.2	174.2
Other	71.0	38.9
Total operating revenue	900.0	690.6

4. OPERATING EXPENSES

	Unaudited 2021 NZ\$M	Unaudited 2022 NZ\$M
For the six months ended 30 September		
Profit before tax includes the following expenses:		
Depreciation - right-of-use assets	6.7	7.7
Depreciation and amortisation - other assets	39.3	42.8
Employee benefits expense	296.3	298.0

5. DERIVATIVE FINANCIAL INSTRUMENTS

Financial instruments are either carried at amortised cost, less any provision for impairment, or fair value. The carrying value of all financial assets and liabilities approximates fair value.

There have been no changes to the Group's hedging policy during the period. The Group enters into foreign currency option contracts or forward foreign currency contracts within policy parameters to manage the net risk associated with anticipated sales or costs. The Group generally applies hedge accounting to all derivative financial instruments.

All derivative financial instruments continue to be re-measured to their fair value. Derivative financial instruments continue to be classified as being within Level 2 of the fair value hierarchy and there were no changes in valuation techniques during the period.

Contractual amounts of derivative financial instruments were as follows:

	Audited 31 March 2022 NZ\$M	Unaudited 30 September 2022 NZ\$M
Foreign currency forward contracts and options		
Sale commitments forward exchange contracts	1,860.5	2,791.3
Purchase commitments forward exchange contracts	97.5	77.6
Foreign currency borrowing forward exchange contracts	49.7	115.1
NZD call option contracts purchased	5.9	-
Collar option contracts - NZD call options purchased (i)	18.2	4.6
Collar option contracts - NZD put options sold (i)	19.4	4.8
Interest rate derivatives		
Interest rate swaps	32.7	39.3

(i) Foreign currency contractual amounts of put and call options are equal.

Undiscounted foreign currency contractual amounts for outstanding hedges were as follows:

	Audited 31 March 2022 M	Unaudited 30 September 2022 M
Sale Commitments		
United States dollars	US\$663.3	US\$1,169.5
European Union euros	€318.2	€317.3
Japanese yen	¥9,945.0	¥8,080.0
Purchase Commitments		
Mexican pesos	MXN\$1,577.0	MXN\$1,282.5

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

6. COMMITMENTS

	Audited 31 March 2022 NZ\$M	Unaudited 30 September 2022 NZ\$M
Capital expenditure commitments contracted for but not recognised as at the reporting date:		
Within one year	56.9	86.6
Between one and two years	6.1	22.3
Between two and five years	-	-
	63.0	108.9

The commitments above exclude the conditional commitment of \$247.5 million payable for the second New Zealand campus as set out in note 2.

7. CONTINGENT LIABILITIES

Periodically the Group is party to litigation including product liability and patent claims. The Directors are unaware of the existence of any claim or contingencies that would have a material impact on the operations of the Group.

8. RELATED PARTY TRANSACTIONS

During the period the Group has not entered into any material contracts involving related parties or Directors' interests. No amounts owed by related parties have been written off or forgiven during the period. Apart from Directors' fees, key executive remuneration and dividends paid by the Group to its Directors as shareholders of the company, there have been no related party transactions.

9. DIVIDENDS

On 24 May 2022 the Directors approved the payment of a fully imputed 2022 final dividend of \$129.9 million (22.5 cents per share) which was paid on 6 July 2022. A supplementary dividend of 3.9706 cents per share was also paid to eligible non-resident shareholders.

Subsequent event - dividend declared

On 28 November 2022 the Directors approved the payment of a fully imputed 2023 interim dividend of \$101.1 million (17.5 cents per share) to be paid on 21 December 2022. A supplementary dividend of 3.09 cents per share was also approved for eligible non-resident shareholders.

10. SIGNIFICANT EVENTS AFTER BALANCE DATE

Other than the dividend disclosed in Note 9, there are no other significant events after balance date.



INDEPENDENT AUDITOR'S REVIEW REPORT

To the shareholders of Fisher & Paykel Healthcare Corporation Limited

REPORT ON THE CONSOLIDATED FINANCIAL STATEMENTS

OUR CONCLUSION

We have reviewed the consolidated financial statements of Fisher & Paykel Healthcare Corporation Limited (the Company) and its subsidiaries (the Group), which comprise the consolidated balance sheet as at 30 September 2022, and the consolidated income statement, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the six months period ended on that date, and other explanatory information.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements of the Group do not present fairly, in all material respects, the financial position of the Group as at 30 September 2022, and its financial performance and cash flows for the six months period then ended on that date, in accordance with International Accounting Standard 34 *Interim Financial Reporting* (IAS 34) and New Zealand Equivalent to International Accounting Standard 34 *Interim Financial Reporting* (NZ IAS 34).

BASIS FOR CONCLUSION

We conducted our review in accordance with the New Zealand Standard on Review Engagements 2410 (Revised) *Review of Financial Statements Performed by the Independent Auditor of the Entity* (NZ SRE 2410 (Revised)). Our responsibilities are further described in the *Auditor's responsibilities for the review of the consolidated financial statements* section of our report.

We are independent of the Group in accordance with the relevant ethical requirements in New Zealand relating to the audit of the annual financial statements, and we have fulfilled our other ethical responsibilities in accordance with these ethical requirements. In addition to our role as auditor, our firm carries out other services for the Group in the areas of executive remuneration benchmarking and providing market survey data, regulatory tax compliance procedures in Mexico, and other assurance services in relation to constant currency disclosures. The provision of these other services has not impaired our independence.

RESPONSIBILITIES OF DIRECTORS' FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The Directors of the Company are responsible on behalf of the Company for the preparation and fair presentation of these consolidated financial statements in accordance with IAS 34 and NZ IAS 34 and for such internal control as the Directors determine is necessary to enable the preparation and fair presentation of the consolidated financial statements that are free from material misstatement, whether due to fraud or error.

INDEPENDENT AUDITOR'S REVIEW REPORT

AUDITOR'S RESPONSIBILITIES FOR THE REVIEW OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our responsibility is to express a conclusion on the consolidated financial statements based on our review. NZ SRE 2410 (Revised) requires us to conclude whether anything has come to our attention that causes us to believe that the consolidated financial statements, taken as a whole, are not prepared in all material respects, in accordance with IAS 34 and NZ IAS 34.

A review of consolidated financial statements in accordance with NZ SRE 2410 (Revised) is a limited assurance engagement. We perform procedures, primarily consisting of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with International Standards on Auditing and International Standards on Auditing (New Zealand) and consequently does not enable us to obtain assurance that we might identify in an audit. Accordingly, we do not express an audit opinion on these consolidated financial statements.

WHO WE REPORT TO

This report is made solely to the Company's Shareholders, as a body. Our review work has been undertaken so that we might state those matters which we are required to state to them in our review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Shareholders, as a body, for our review procedures, for this report, or for the conclusion we have formed.

The engagement partner on the review resulting in this independent auditor's review report is Keren Blakey.

For and on behalf of:



Chartered Accountants

28 November 2022

Auckland, New Zealand

Directory

DIRECTORS

Scott St John	Board Chair, Non-Executive, Independent
Lewis Gradon	Managing Director and Chief Executive Officer
Michael Daniell	Non-Executive
Pip Greenwood	Non-Executive, Independent
Lisa McIntyre	Non-Executive, Independent
Neville Mitchell	Non-Executive, Independent
Donal O'Dwyer	Non-Executive, Independent
Cather Simpson	Non-Executive, Independent

EXECUTIVE MANAGEMENT TEAM

Lewis Gradon	Managing Director and Chief Executive Officer
Lyndal York	Chief Financial Officer
Paul Shearer	Senior Vice President – Sales & Marketing
Andrew Somervell	Vice President – Products & Technology
Winston Fong	Vice President – Surgical Technologies
Brian Schultz	Vice President – Quality & Regulatory Affairs
Nicholas Fourie	Vice President – Information & Communication Technology
Jonti Rhodes	Vice President – Supply Chain, Facilities & Sustainability
Marcus Driller	Vice President – Corporate
Nicola Talbot	Vice President – Human Resources

REGISTERED OFFICES

New Zealand:

Physical address:	15 Maurice Paykel Place, East Tamaki, Auckland 2013, New Zealand
Telephone:	+64 9 574 0100
Postal address:	PO Box 14348, Panmure, Auckland 1741, New Zealand
Website:	www.fphcare.com
Email:	investor@fphcare.co.nz

Australia:

Physical address:	19-31 King St, Nunawading, Melbourne, Victoria 3131, Australia
Telephone:	+61 3 9871 4900
Postal address:	PO Box 159, Mitcham Victoria 3132, Australia

STOCK EXCHANGES

The Company's ordinary shares are listed on the NZX Main Board and the ASX.

SHARE REGISTRAR

In New Zealand:

Link Market Services Limited


Physical address:	Level 30, PwC Commercial Bay, 15 Customs Street West, Auckland 1010, New Zealand
Postal address:	PO Box 91976, Auckland 1142, New Zealand
Facsimile:	+64 9 375 5990
Investor enquiries:	+64 9 375 5998
Website:	www.linkmarketservices.co.nz
Email:	enquiries@linkmarketservices.co.nz

In Australia:

Link Market Services Limited

Physical address:	Level 12, 680 George Street, Sydney, NSW 2000, Australia
Postal address:	Locked Bag A14, Sydney South, NSW 1235, Australia
Facsimile:	+61 2 9287 0303
Investor enquiries:	+61 2 8280 7111
Internet address:	www.linkmarketservices.com.au
Email:	registrars@linkmarketservices.com.au





Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea.

COMMITMENT



Important notice

Disclaimer

The information in this presentation is for general purposes only and should be read in conjunction with Fisher & Paykel Healthcare Corporation Limited's (FPH) Interim Report 2023 and accompanying market releases. Nothing in this presentation should be construed as an invitation for subscription, purchase or recommendation of securities in FPH.

This presentation includes forward-looking statements about the financial condition, operations and performance of FPH and its subsidiaries. These statements are based on current expectations and assumptions regarding FPH's business and performance, the economy and other circumstances. As with any projection or forecast, the forward-looking statements in this presentation are inherently uncertain and susceptible to changes in circumstances. FPH's actual results may differ materially from those expressed or implied by those forward-looking statements.

Constant currency information included within this presentation is non-GAAP financial information, as defined by the NZ Financial Markets Authority, and has been provided to assist users of financial information to better understand and track the company's comparative financial performance without the impacts of spot foreign currency fluctuations and hedging results and has been prepared on a consistent basis each year. A reconciliation between reported results and constant currency results is available in the company's Interim Report 2023. The company's constant currency framework can be found on the company's website at www.fphcare.com/ccf.

Half year business highlights

CONTINUED to build out our anesthesia sales force in Europe and North America.

ENTERED into conditional agreement for land to construct our second New Zealand campus.

PROGRESSED the roll-out of our new technology, including Airvo 3, Optiflow Switch and Evora Full.

ADVANCED construction of our fifth facility at our first New Zealand campus.

COMPLETED the construction of our third manufacturing facility in Tijuana.

PRESENTED with four social responsibility awards by the Association of Human Resources in Tijuana.

Key half year financial results

H1 FY23 (6 months to 30 September 2022)

	% of Revenue	NZ\$M	ΔPCP^	ΔCC*
Operating revenue	100%	690.6	-23%	-27%
Hospital operating revenue	64%	438.7	-35%	-37%
Homecare operating revenue	36%	249.9	10%	4%
Gross margin / Gross profit	60%	413.2	-325bps	-533bps
SG&A	29%	(202.3)	7%	0%
R&D	12%	(84.2)	11%	11%
Total operating expenses	41%	(286.5)	8%	3%
Operating profit	18%	126.7	-58%	-67%
Profit after tax	14%	95.9	-57%	-65%

Hospital product group



H1 FY22 Hospital revenue composition
Hardware: 33% Consumables: 67%

Hospital product group

H1 FY23

64% OF OPERATING REVENUE

HOSPITAL OPERATING REVENUE

\$438.7M

NZ\$ -35%


CONSTANT CURRENCY -37%

NEW APPLICATIONS CONSUMABLES REVENUE *

NZ\$ -20%

CONSTANT CURRENCY -23%


Impacted by COVID-19 driven demand for hospital respiratory products



- Sales of our Optiflow consumables were impacted by elevated levels of stock purchased in preparation for Omicron
- New applications consumables* made up 68% of H1 FY23 Hospital consumables revenue, 72% in H1 FY22
- H1 FY23 Hospital hardware revenue remained above pre-COVID levels, 74% down on FY22 in constant currency

Homecare product group

H1 FY23 HOMECARE REVENUE COMPOSITION



■ Hardware ■ Consumables

HARDWARE



F&P SleepStyle



F&P myAIRVO 2



F&P 810 System

CONSUMABLES



CPAP Therapy/OSA



Home Respiratory Support



F&P Evora Full



F&P Evora



F&P Brevida



H1 FY22 Homecare revenue composition
Hardware: 18% Consumables: 82%

Homecare product group

H1 FY23

36% OF OPERATING REVENUE


**HOME CARE
OPERATING
REVENUE**

\$249.9M

NZ\$ 10%
CONSTANT CURRENCY 4%

**MASKS
REVENUE**

NZ\$ 16%
CONSTANT CURRENCY 10%




F&P Evora Full




- Strong contribution from F&P Evora Full following successful launch in the US
- OSA mask revenue was impacted by reduced new patient starts, due to the limited supply of treatment hardware

Gross Margin



- Gross margin for the half year:
 - decreased by 325 bps to 59.8%
 - decreased by 533 bps in constant currency
- Continued elevated freight costs and air freight utilisation impacted constant currency gross margin by approximately ~290 basis points compared to pre-COVID-19 rates
- Manufacturing inefficiencies experienced as we balance demand fluctuations with manufacturing throughput

Operating Margin



Operating expenses

- \$286.5M, +8% (+3% CC)
- Operating margin decreased by 1,526 bps (-1,770bps CC) to 18.3% with continued investment in operating expenses to support COVID-19 driven hardware sales and accelerate future product pipeline

Research & Development expenses

- \$84.2M, +11% (+11% CC)
- Reflecting underlying growth and timing of R&D projects
- Estimate ~60% of R&D spend eligible for tax credit

Selling, General & Administrative expenses


- \$202.3M, +7% (0% CC)

Cash Flow and Balance Sheet

	H1 FY22 NZ\$M	H1 FY23 NZ\$M
Operating cash flow	127.5	1.9
Capital expenditure (including purchases of intangible assets)	81.3	124.8
Lease liability payments	6.6	6.7
Free cash flow	39.6	(129.6)
	FY22 NZ\$M	H1 FY23 NZ\$M
Net cash / (debt) (including short-term investments)	221.6	(42.6)
Total assets	2,107.0	2,094.5
Total equity	1,679.7	1,478.4
Gearing (net debt / net debt + equity)*	-16.3%	2.7%

Dividend

- Increased interim dividend by 3%
 - 17.50 cps + 6.8056 cps imputation credit for NZ residents (gross dividend of NZ 24.3056 cps)
 - Fully imputed
 - 3.0882 cps non-resident supplementary dividend
- The company's dividend reinvestment plan has been reactivated with a 3% discount



Foreign exchange effects

- 45% of operating revenue in US\$ (FY22: 49%) and 20% in € (FY22: 17%).

Year to 31 March

Hedging position for our main exposures (as at 10 November 2022)	FY23	FY24	FY25	FY26	FY27	FY28	FY29- FY31+
USD % cover of estimated exposure	90%	80%	65%	55%	50%	25%	5%
USD average rate of cover	0.667	0.658	0.622	0.608	0.596	0.585	0.526
EUR % cover of estimated exposure	85%	60%	50%	30%	20%	10%	-
EUR average rate of cover	0.542	0.536	0.521	0.529	0.517	0.521	-


Hedging cover percentages have been rounded to the nearest 5%

Reconciliation of Constant Currency to Actual Income Statements	H1 FY22 NZ\$M	H1 FY23 NZ\$M
Profit after tax (constant currency)	204.1	72.1
Spot exchange rate effect	0.1	22.6
Foreign exchange hedging result	15.2	0.4
Balance sheet revaluation	2.4	0.8
Profit after tax (as reported)	221.8	95.9

Revenue and expenses by currency


H1 FY23 (for the 6 months ended 30 September 2022)

REVENUE BY CURRENCY




■ NZD ■ USD ■ EUR ■ MXN ■ Other

COST OF SALES BY CURRENCY




■ NZD ■ USD ■ EUR ■ MXN ■ Other

OPERATING EXPENSES BY CURRENCY



■ NZD ■ USD ■ EUR ■ MXN ■ Other

Our aspiration



OUR ASPIRATION:
Sustainably
DOUBLING
our constant
currency revenue
every 5-6 years.

The image above is an illustration of the company's long-term growth aspirations. It is not a graph and should not be interpreted as being indicative of levels of revenue or profitability in the short term.

Looking ahead

Given the uncertainties outlined in the company's news release dated 29 November 2022, we are not providing full-year quantitative revenue or earnings guidance at this time.

However, we expect H2 FY23 revenue will be higher than H1 FY23 revenue.

Hospital product group

- Pre-COVID-19 seasonal patterns have typically resulted in higher sales of hospital consumables in the second half compared to the first half.*
- It is likely that a proportion of customers have worked through Omicron-driven consumables stock during H1 FY23.

Homecare product group

- We believe the recent launch of our new Evora Full face mask, combined with improving global supply of CPAP hardware, will contribute to continued growth for the remainder of the year.

Gross margin and operating expenses

- Assuming current, slightly lower freight costs and reduced manufacturing inefficiencies, constant currency gross margin for H2 FY23 would improve from the first half by approximately 200 basis points.
- The company is now targeting constant currency operating expense growth of approximately 8% for the full year.
- Based on these assumptions and at 31 October 2022 exchange rates (NZD:USD 0.58, NZD:EUR 0.58), reported gross margin for H2 FY23 would be ~61% and FY23 operating expense growth would be ~14%.

「Overview」



Fisher & Paykel Healthcare at a glance

Global leader in respiratory humidification devices

- Medical device manufacturer with leading positions in respiratory care and obstructive sleep apnea
- >50 years' experience in changing clinical practice to solutions that provide better clinical outcomes and improve effectiveness of care
- Estimated NZ\$25+ billion and growing market opportunity driven by demographics
- Significant organic long-term growth opportunities in acute and chronic respiratory care, OSA and surgery
- Large proportion (86%) of revenue from recurring items, consumables and accessories
- High level of innovation and investment in R&D with strong product pipeline
- High barriers to entry

Global presence

Our people
are located in
54 countries



3,502

in New Zealand

2,001

in North America,
including Mexico

365

in Europe

483

in the rest
of the world

Strong financial performance

- Continued target, and history of, doubling our revenue (in constant currency terms) every 5 to 6 years
- Targeting gross margin of 65% and operating margin of 30%
- Growth company with a strong history of increasing dividend payments

~NZ\$25+ billion and growing market opportunity

Total addressable market estimates

HOSPITAL

~150+ million patients

Invasive Ventilation



Noninvasive Ventilation



Hospital Respiratory Support



Anesthesia



Infant Care



Surgical



NEW APPLICATIONS

Applications outside of invasive ventilation





HEMOCARE

~100+ million patients

Home Respiratory Support




Obstructive Sleep Apnea








Our aspiration



OUR ASPIRATION:
Sustainably
DOUBLING
our constant
currency revenue
every 5-6 years.

Consistent growth strategy



F&P product fundamentals



What are we here to do?

A drive to not only improve, but transform,
clinical practice.

Provide products with protected, value
differentiation.

Get our products, including the evidence, knowledge
and supporting tools, into the hands of the customer

_____ A deep understanding of the problem and knowing what we _____
are trying to achieve, leads to valued, innovative solutions

A patient-focused approach

A drive to deliver and improve

Long-term thinking

High level of innovation and investment in R&D




- R&D represents 12% of operating revenue*: NZ\$84.2M
- Product pipeline includes:
 - Humidifier controllers
 - Masks
 - Respiratory consumables
 - Flow generators
 - Compliance monitoring solutions
- 492 US patents, 518 US pending, 2140 Rest of World patents, 1617 Rest of World pending†



Growing patent portfolio



FISHER & PAYKEL HEALTHCARE US PATENT PORTFOLIO (2008 – 2022)



Average remaining life of FPH patent portfolio (all countries): 11.3 years*

Changing Clinical Practice



- Using clinical evidence to drive change
- Multi-layered with multiple stakeholders
- Building confidence with usage inline with the evidence, demonstrating value
- Products in each care area builds familiarity and confidence
- Customer experience builds trust and confidence



Strong global presence



- **Direct/offices**

- Hospitals, home care dealers
- Sales/support offices in North America, Europe, Asia, South America, Middle East and Australasia, 18 distribution centres
- ~1,300 employees in 53 countries
- Ongoing international expansion

- **Distributors**


- +180 distributors worldwide

- **Original Equipment Manufacturers**

- Supply most leading ventilator manufacturers

- **Sell in more than 120 countries**

Revenue by Region
6 months to 30 September 2022



「 Hospital 」



Impact of changing demographics


Population age and weight both increasing

- Global population 60 years+ is expected to more than double over the next 30 years¹
- 18% of adults are forecast to be obese by 2030²


40-50% of healthcare spend is on persons 65 years and older, in OECD countries³

Low-upper middle income markets increasing healthcare spending

- Total health spending is increasing more rapidly in low-upper middle income countries (4 to 5% on average) than in high income countries (~2%)⁴




Hospital cost breakdown



Lower care intensity = lower cost

MEAN ANNUAL COPD-RELATED MEDICAL, PHARMACY
AND TOTAL COSTS BY CARE INTENSITY COHORT



Respiratory humidification


- Normal airway humidification is bypassed or compromised during ventilation or oxygen therapy
- Mucociliary transport system operates less effectively
- Need to deliver gas at physiologically normal levels
 - 37°C body core temperature
 - 44mg/L 100% saturated



Optiflow nasal high flow therapy

Mechanisms of action

Spontaneously breathing patients with or at risk of respiratory compromise



Optiflow - displacing conventional oxygen therapy

CONVENTIONAL OXYGEN THERAPY



Low flow nasal prongs



Simple face mask



Rebreather mask

NON-INVASIVE VENTILATION



F&P **Optiflow**
Nasal high flow therapy

Patient groups who may benefit from Optiflow

ADULTS:

- Acute respiratory failure
- Asthma
- Atelectasis
- Bronchiectasis
- Bronchitis
- Burns
- COPD
- Chest trauma
- Emphysema
- Palliative Care
- Pneumonia
- Pulmonary embolism
- Respiratory compromise
- Viral pneumonia
- Carbon monoxide poisoning

PAEDIATRICS/NEONATES:

- Infant respiratory distress
- Bronchiolitis




Clinical practice guidelines: Nasal high flow therapy

Society and recommendations

	European Society of Intensive Medicine ESICM	European Respiratory Society ERS	Society of Critical Care Medicine SCC	American Association of Respiratory Care AARC	American College of Physicians ACP
HFNC over COT in hypoxemic ARF	●	●			
HFNC over NIV in hypoxemic ARF		●	●		●
HFNC over COT post-extubation	●	●		●	●
HFNC in high risk and/or obese patients following cardiac or thoracic surgery	●				
HFNC over COT during breaks from NIV		●			
HFNC or COT in post-operative patients at low risk of pulmonary complications		●			
HFNC or NIV in post-operative patients at high risk of pulmonary complications		●			
HFNC to avoid escalation to NIV				●	


Optiflow NHF - a growing body of clinical evidence

NASAL HIGH FLOW CLINICAL PAPERS PUBLISHED ANNUALLY



- The publication of 858 clinical papers on NHF signifies the high level of clinical interest in the therapy through the pandemic

History of growth in hospital new applications



New applications consumables: Non-invasive ventilation, Optiflow, Anesthesia, Surgical
* Adjusted to exclude impact of US distribution transition in FY16 and FY17

「 Homecare



Obstructive Sleep Apnea

- Obstructive sleep apnea is an underdiagnosed medical condition, with multiple negative outcomes to patients' health.
- It can greatly impair quality of sleep, leading to fatigue; also associated with hypertension, stroke and heart attack
- Estimate >100 million people affected in developed countries
- Most common treatment is CPAP (Continuous Positive Airway Pressure)
 - Key issue with CPAP is compliance
 - Humidification provides significant acceptance and compliance improvements



Mask matters most


- Masks are key to compliance
- Unique, patented designs
- Released our new Evora™ Full OSA mask in the United States.



F&P EVORA NASAL™
F&P Evora



F&P EVORA FULL-FACE™
F&P Evora Full



F&P BREVIDA™
F&P Brevida

Home respiratory support

- Chronic obstructive pulmonary disease (COPD) is a lung disease which is commonly associated with smoking
- Emphysema and chronic bronchitis are both forms of COPD
- Chronic respiratory disease, primarily COPD, is the third leading cause of death in the world¹⁷
- 6% of US adults have been diagnosed with COPD¹⁸ (~15 million people)
- 4-10% COPD prevalence worldwide¹⁹ (~400 million people)
- Emerging evidence for COPD patients using NHF at home, reduced exacerbation rates¹⁰, reduced hypercapnia^{27,28}, and improved quality of life^{10,27}.



Manufacturing and operations

New Zealand

- Four buildings: 110,000 m² / 1,180,000 ft²
- Co-location of R&D and manufacturing
- Continued earthworks on building 5
- Entered into conditional agreement for additional 105 hectare campus

Tijuana, Mexico

- Three buildings: 63,000 m² / 690,000 ft²

Future manufacturing

- Entered lease agreement for a facility in Guangzhou, China. The new facility is aligned with our distributed manufacturing strategy, and our intent is to manufacture a select range of products to service local markets.



Conditional agreement to purchase second R&D and manufacturing campus in Karaka, Auckland

Environmental, Social & Governance

Our People

The Board approved a discretionary profit-sharing payment of \$4 million for company employees. Our people have continued to overcome supply chain issues, challenging operational schedules and spikes in absenteeism related to COVID-19.

Community and Volunteer Groups

We are proud of the community groups supported through the Fisher & Paykel Healthcare Foundation and the work of the following F&P volunteer groups:

- Manaaki (indigenous leadership)
- Spectra
- Women in Engineering

Refer to our 2022 Annual Report for more details.

Sustainable Procurement

FY22 Highlights:

- Articulated a new Environmental & Social Responsibility Policy
- Commenced supplier engagement on modern slavery (covering ~35% of overall supplier spend)
- Initiated modern slavery observations as part of supplier site visits

Key Environmental Metrics

	FY20	FY21	FY22
Scope 1 emissions (tonnes CO ₂ e)	1,914	1,465	1,777
Scope 2 emissions (tonnes CO ₂ e)	8,814	11,050	10,309
Scope 3 emissions (tonnes CO ₂ e)	650,000	718,991	457,112
Total emissions (tonnes CO ₂ e)	660,728	734,452	469,198
Water usage (cubic metres)	98,772	134,900	184,171
Landfill waste diverted (cubic metres)	1,032	1,630	2,035
NZ recycling efficiency (percentage of waste diverted from landfill)	66%	62%	68%
Global recycling efficiency (percentage of waste diverted from landfill)	58%	29%	52%

Sustainability disclosures and indices

We participate annually in a suite of well-respected sustainability disclosure programmes and are included in the Dow Jones Sustainability Index and the FTSE4Good index.

Member of

Dow Jones Sustainability Indices

Powered by the S&P Global CSA




FTSE4Good




Ownership structure and listings

- Listed on NZX and ASX (NZX.FPH, ASX.FPH)

Shareholding structure as at
30 September 2022



Geographical ownership as at
30 September 2022



References

References

1. (2022). Ageing and health. World Health Organization. <https://www.who.int/news-room/fact-sheets/detail/ageing-and-health>
2. Lobstein, T., & Brinsden, H. (2022, March 10). World Obesity Atlas 2022. World Obesity.
3. Safiliou-Rothschild, C. (2009). ARE OLDER PEOPLE RESPONSIBLE FOR HIGH HEALTHCARE COSTS? CESifo Forum..
4. Global Burden of Disease Health Financing Collaborator Network. Future and potential spending on health 2015-40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. *Lancet*. 2017 May 20;389(10083):2005-2030. doi: 10.1016/S0140-6736(17)30873-5. Epub 2017 Apr 19. Erratum in: *Lancet*. 2017 May 20;389(10083):1980. PMID: 28433260; PMCID: PMC5440765.
5. KeX, Agnes S et al. Public Spending on Health: A Closer Look at Global Trends. World Health Organisation 2018.
6. Frat JP, Thille AW, Mercat A et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *N Engl J Med*. 2015;372(23):2185-96
7. Maggiore SM, Idone FA, Vaschetto R et al. Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. *Am J Respir Crit Care Med*. 2014;190(3):282-8
8. Stéphan F, Barrucand B, Petit P et al. High-Flow Nasal Oxygen vs Noninvasive Positive Airway Pressure in Hypoxemic Patients After Cardiothoracic Surgery: A Randomized Clinical Trial. *JAMA*. 2015;313(23):2331-9
9. Hernández G, Vaquero C, González P, et al. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial. *JAMA*. 2016;315(13):1354-1361. doi:10.1001/jama.2016.2711
10. Storgaard LH, Hockey HU, Laursen BS, Weinreich UM. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. *Int J Chron Obstruct Pulmon Dis* 2018;16;13:1195-1205
11. Wing R, James C, Maranda LS et al. Use of high-flow nasal cannula support in the emergency department reduces the need for intubation in pediatric acute respiratory insufficiency. *Pediatr Emerg Care*. 2012;28(11):1117-23
12. McKiernan C, Chua LC, Visintainer PF et al. High flow nasal cannulae therapy in infants with bronchiolitis. *J Pediatr*. 2010;156(4):634-8
13. Milési C, Baleine J, Matecki S et al. Is treatment with a high flow nasal cannula effective in acute viral bronchiolitis? A physiologic study. *Intensive Care Med*. 2013 Jun;39(6):1088-94
14. Manley BJ, Owen LS, Doyle LW et al. High-flow nasal cannulae in very preterm infants after extubation. *N Engl J Med*. 2013;369(15):1425-33
15. Yoder BA, Stoddard RA, Li M, King J et al. Heated, humidified high-flow nasal cannula versus nasal CPAP for respiratory support in neonates. *Pediatrics*. 2013;131(5):e1482-90
16. Collins CL, Holberton JR, Barfield C, Davis PG. A randomized controlled trial to compare heated humidified high-flow nasal cannulae with nasal continuous positive airway pressure postextubation in premature infants. *J Pediatr*. 2013;162(5):949-54
17. Saslow JG, Aghai ZH, Nakhla TA et al. Work of breathing using high-flow nasal cannula in preterm infants. *J Perinatol*. 2006;26(8):476-80
18. World Health Organisation (2018) The top 10 causes of death. Available at: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death> (Accessed: 24 May 2018)
19. Nicole M Kosacz, Antonello Punturieri et al. Chronic Obstructive Pulmonary Disease Among Adults -United States 2011. US Centers for Disease Control and Prevention, 2012.
20. R J Halbert, Sharon Isonaka, Dorothy George, Ahmar Iqbal. Interpreting COPD Prevalence Estimates. *Chest*. 2003; 123:5 1684 – 1692.
21. Rochwerg B, Granton D, Wang DX et al (2019) High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. *Intensive Care Med* 45(5):563–572.
22. Chaudhuri D, Granton D, Wang DX, Burns KEA, Helviz Y, Einav S, Trivedi V, Mauri T, Ricard JD, Mancebo J, Frat JP, Jog S, Hernandez G, Maggiore SM, Mbuagbaw L, Hodgson CL, Jaber S, Goligher EC, Brochard L, Rochwerg B. High-Flow Nasal Cannula in the Immediate Postoperative Period: A Systematic Review and Meta-analysis. *Chest*. 2020 Nov;158(5):1934-1946. doi: 10.1016/j.chest.2020.06.038. Epub 2020 Jun 29. PMID: 32615190..
23. Chaudhuri D, Granton D, Wang DX et al (2020) Moderate certainty evidence suggests the use of high-flow nasal cannula does not decrease hypoxia when compared with conventional oxygen therapy in the peri-intubation period: results of a systematic review and meta-analysis. *Critical Care Med*.
24. Granton D, Chaudhuri D, Wang D, et al. High-Flow Nasal Cannula Compared With Conventional Oxygen Therapy or Noninvasive Ventilation Immediately Postextubation: A Systematic Review and Meta-Analysis. *Crit Care Med*. 2020;48(11):e1129-e1136. doi:10.1097/CCM.0000000000004576.
25. Rochwerg B, Einav S, Chaudhuri D, et al. The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline. *Intensive Care Med*. 2020;46(12):2226-2237. doi:10.1007/s00134-020-06312-y.
26. Millar J, Lutton S, O'Connor P. The use of high-flow nasal oxygen therapy in the management of hypercarbic respiratory failure. *Ther Adv Respir Dis*. 2014;8(2):63–64. doi:10.1177/1753465814521890..
27. Pavlov I, Plamondon P, Delisle S. Nasal high-flow therapy for type II respiratory failure in COPD: a report of four cases. *Respir Med Case Rep*. 2017;20:87–88. doi:10.1016/j.rmcr.2016.12.006.
28. Rittayamai N, Phuangchoei P, Tscheikuna J, et al. Effects of high-flow nasal cannula and non-invasive ventilation on inspiratory effort in hypercapnic patients with chronic obstructive pulmonary disease: a preliminary study. *Ann Intensive Care*. 2019; 9(1):122doi:10.1186/s13613-019-0597-5.

29 November 2022

Results announcement

Results for announcement to the market		
Name of issuer	Fisher & Paykel Healthcare Corporation Limited	
Reporting Period	6 months to 30 September 2022	
Previous Reporting Period	6 months to 30 September 2021	
Currency	NZD	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$690,600	-23%
Total Revenue	\$690,600	-23%
Net profit/(loss) from continuing operations	\$95,900	-57%
Total net profit/(loss)	\$95,900	-57%
Interim Dividend		
Amount per Quoted Equity Security	0.17500000 \$/share	
Imputed amount per Quoted Equity Security	0.06805556 \$/share	
Record Date	09 December 2022	
Dividend Payment Date	21 December 2022	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	2.11489847 \$/share	2.42989359 \$/share
A brief explanation of any of the figures above necessary to enable the figures to be understood	Not applicable	
Authority for this announcement		
Name of person authorised to make this announcement	Raelene Leonard	
Contact person for this announcement	Raelene Leonard	
Contact phone number	+64 9 574 0147	
Contact email address	companysecretary@fphcare.co.nz	
Date of release through MAP	29 November 2022	

Reviewed financial statements accompany this announcement.

29 November 2022
Distribution Notice

Section 1: Issuer information				
Name of issuer	Fisher & Paykel Healthcare Corporation Limited			
Financial product name/description	Interim Dividend			
NZX ticker code	FPH			
ISIN	NZFAPE0001S2			
Type of distribution	Full Year		Quarterly	
	Half Year	X	Special	
	DRP applies	X		
Record date	09 December 2022			
Ex-Date	08 December 2022			
Payment date	21 December 2022			
Total monies associated with the distribution	\$101,095,044 million based on shares on issue at 28 November 2022 for cash distribution			
Source of distribution	Retained earnings			
Currency	NZD			
Section 2: Distribution amounts per financial product				
Gross distribution	0.24305556 \$/share			
Gross taxable amount	0.24305556 \$/share			
Total cash distribution	0.17500000 \$/share			
Excluded amount	N/A			
Supplementary distribution amount	0.03088235 \$/share			
Section 3: Imputation credits and Resident Withholding Tax				
Is the distribution imputed	Fully imputed			
If fully or partially imputed, please state imputation rate as % applied	100%			
Imputation tax credits per financial product	0.06805556 \$/share			
Resident Withholding Tax per financial product	0.01215278 \$/share			
Section 4: Distribution re-investment plan (if applicable)				
DRP % discount (if any)	3.0 %			
Start date and end date for determining market price for DRP	12 December 2022		16 December 2022	
Date strike price to be announced (if not available at this time)	19 December 2022			
Specify source of financial products to be issued under DRP programme	New Issue			

(new issue or to be bought on market) DRP strike price per financial product	
Last date to submit a participation notice for this distribution in accordance with DRP participation terms	12 December 2022
Section 5: Authority for this announcement	
Name of person authorised to make this announcement	Raelene Leonard
Contact person for this announcement	Raelene Leonard
Contact phone number	+64 9 574 0147
Contact email address	companysecretary@fphcare.co.nz
Date of release through MAP	29 November 2022